Cryo-Cell's Affiliate, Saneron CCEL Therapeutics, Releases Pre-clinical Data Indicating That Cord Blood Stem Cells …

Repeated injections of human umbilical cord blood cells improved motor neuron survival, delayed disease progression and increased lifespan

Oldsmar, FL (PRWEB) March 06, 2012

Dr. Julie G. Allickson, PhD. Vice President of Laboratory Operations and R&D, stated This groundbreaking study demonstrates the amazing capacity of cord blood stem cells to potentially treat a devastating neurodegenerative disease through the secretion of trophic factors that resulted in neuroprotection in the ALS mouse model. The data certainly justifies additional pre-clinical investigations using umbilical cord blood stem cells. This source of cells has mainly been used in hematopoietic and immune diseases in more than 25,000 transplants to date.

Cryo- Cell is excited about the results of the research Saneron CCEL Therapeutics has completed and proud of the progress Saneron has made in the treatment for ALS. The investment community does not appreciate the value of Cryo-Cells holdings in Saneron and its world-class research initiatives, commented David Portnoy, Cryo-Cells Chairman and CEO.

Given the delay between the onset of symptoms and the actual diagnosis of ALS, the data obtained from this study was critically important to show that multiple low-doses of cord blood cells started after the symptomatic disease stage in the ALS mouse model could benefit disease outcomes, said co-author Nicole Kuzmin-Nichols, President and COO of Saneron CCEL Therapeutics, Inc. Our continuing studies are aimed at translating the preclinical data into future clinical studies.

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. was founded in 1989 and was the worlds first private cord blood bank to separate and store stem cells in 1992. Today, Cryo-Cell has over 240,000 clients worldwide from 87 countries. Cryo-Cells mission is to provide our clients with the premier stem cell cryopreservation service and to support the advancement of regenerative medicine.

Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility, is ISO 9001:2008 certified and accredited by the AABB. Cryo-Cell is a publicly traded company. OTC:QB Markets Group Symbol: CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit

About Saneron CCEL Therapeutics, Inc.

Saneron CCEL Therapeutics, Inc. is a biotechnology R&D company, focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of Cryo-Cell International, Inc., Saneron is committed to providing readily available, noncontroversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.

View original post here:
Cryo-Cell's Affiliate, Saneron CCEL Therapeutics, Releases Pre-clinical Data Indicating That Cord Blood Stem Cells ...

Related Post